Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
FDA committee votes in favor of BPC-157 and KPV peptides This title was summarized by AI from the post below
Component Test Results Labeled content and literal tested-content results are disclosed separately for every component
Critical Safety Gaps for Mental Health Applications Unknown effects on cognitive function, memory, personality, mood stability beyond intended therapeutic effect Long-term impacts on brain chemistry (chronic administration effects unexplored beyond 6 weeks in animals) Potential for psychological dependence or tolerance (not studied systematically) Impacts on developing brains in adolescents and young adults (completely unknown with no pediatric studies) Drug Interactions Pose Serious Concerns BPC-157s simultaneous effects on serotonin, dopamine, GABA, glutamate, and nitric oxide systems create multiple theoretical interaction points with psychiatric medications, yet interactions are not well studied. Specific concerns include: With SSRIs and SNRIs: Risk of serotonin syndrome is genuine
doi:10.1111/1471-0528.13574
Insulin increases NADH/NAD+ redox state, which stimulates guanylate cyclase in [PMID: 11939620] Laboratory literature summary: Insulin increases NADH/NAD+ redox state, which stimulates guanylate cyclase in vascular smooth muscle
